1. To understand the personal experience of an individual who participated in the 2021 COMPASS psilocybin trial for treatment-resistant depression, offering a unique perspective beyond the clinical results. 2. To examine the current clinical methods of measuring the effectiveness of treatment in the trial, particularly psilocybin's impact on patients labelled as "non-responders". 3. To discern the potential inadequacies of data-driven models in capturing the substantial therapeutic impacts of psychedelic drugs on individuals with treatment-resistant depression. 4. To assess the benefits and potential limitations of psychedelic-assisted therapy based on firsthand patient experiences. 5. To explore the implications of patient narratives on future clinical practices and research methodologies in psychedelic-assisted therapy.